BioNTech SE
Clinical trials sponsored by BioNTech SE, explained in plain language.
A biotechnology company developing immunotherapies, including mRNA-based vaccines and cancer treatments.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- BioNTech launches first human test of mRNA herpes vaccine Results expected Oct 2026 (estimated)
- New antibody BNT351 enters first human trial for HIV Results expected Nov 2026 (estimated)
- New vaccine aims to stop colorectal cancer recurrence in High-Risk patients Results expected Nov 2026 (estimated) May already have reported ↗
- Can updated COVID-19 shots better protect High-Risk groups? Results expected Apr 2027 (estimated)
- New combo therapy takes on tough lung cancer Results expected Jun 2027 (estimated)